Drug for Osteoarthritis
  • Degenerative arthritis (OA) is a major disease of the elderly, mainly caused by aging of the joints, but it also causes joints such as genetic cause, nutritional imbalance, lack of exercise, extreme exercise or injury. It frequently in the younger age because it is caused by various factors such as behavior, wrong posture, and overload caused by obesity.

    When trauma or degenerative changes weaken the tissues that support the joints, they damage the cartilage tissue that is cushioning, increasing the friction between the bones and causing pain and inflammation. Inflammation promotes osteophyte formation around the joints, limiting mobility and causing greater pain. Once damaged cartilage tissue is naturally not regenerated or restored, it limits the social activity of the patient for a long time and deteriorates the quality of life.

    Therapeutic methods to date include conservative therapies such as exercise, diet, injection therapy, drug therapy including body weight control, tissue regeneration using growth factor, transplantation using artificial cultured cells Implantation), and surgical interventions such as artificial joint replacement, which is used in cases of severe damage. However, there is no cure to restore and repair damaged cartilage tissue fundamentally more simply and stably. Therefore, the development of a new concept of arthritis treatment is urgently required.

    Engedi 1000 (E1K) is a natural peptide substance that prevents arthritic cartilage degeneration, regenerates articular cartilage, and also relieves pain. This effect of Engedi 1000 is because it regulates the signaling pathway of TGF-beta1, a protein that promotes degeneration of articular cartilage tissue. Engedi 1000 selectively binds Smad1/5/8 pathway, which is coupled to TGF-beta1, to promote cartilage tissue degeneration, and maintains the Smad2/3 pathway that induces cartilage tissue regeneration, And also reduces the painful factor NGF (G) gene expression, thereby reducing pain.